Alessandro  Sette, Dr.Biol.Sci.

Alessandro Sette, Dr.Biol.Sci.

La Jolla Institute for Immunology

Professor

Expertise: ImmunologyImmunology

Dr. Alessandro Sette has devoted more than 35 years of study towards understanding the immune response, measuring immune activity, and developing disease intervention strategies against cancer, autoimmunity, allergy, and infectious diseases. The laboratory is defining in chemical terms the specific structures (epitopes) that the immune system recognizes, and uses this knowledge to measure and understand immune responses.

The Sette lab’s approach uses epitopes as specific probes to define the immune signatures associated with productive/protective immunity versus deficient immunity/immunopathology. This research will improve understanding of how the body successfully battles infection, and conversely, how pathogens escape the immune system, causing the individual to succumb to disease. Because of the laboratory’s success in its study of immune response, Sette and his team believe their research will lead to development of new therapeutic and prophylactic approaches to fighting infectious diseases. In this area, Dr. Sette’s disease focus has shifted over the years from HIV, HBV and HCV to emerging diseases and diseases of potential biodefense concern to, most recently, diseases and pathogens relevant to worldwide global health, including SARS-CoV-2, Dengue, Zika, Chikungunya, malaria, M. tuberculosis, B. pertussis, and shingles. Furthermore, Dr. Sette’s team has adapted the methods and techniques developed in the context of infectious disease to understand the T cell response to common allergens and to discover a cell component in Parkinson’s Disease.

Finally, Dr. Sette has overseen the design and curation efforts of the national Immune Epitope Database (IEDB), a freely available, widely used bioinformatics resource, since its inception in the early 2000s. The IEDB catalogs all epitopes for humans, non-human primates, rodents, and other vertebrates, from allergens, infectious diseases, autoantigens and transplants, and includes epitope prediction tools to accelerate immunology research around the world.

Title

Cited By

Year

Dengue: An Emerging Global Crisis - Research and Expert Insights

Calling All Experts and Researchers: Share Your Insights on Dengue, Prevention, Detection and Vaccines.
15-Apr-2024 08:30:44 AM EDT

LJI scientists confirm smallpox vaccine also teaches T cells to fight mpox

"Vaccines such as JYNNEOS should be able to induce T cells that also recognize mpox and can provide protection from severe disease."
06-Dec-2022 08:30:18 PM EST

LJI scientists reflect on what it means to make the “Highly Cited” list

Seven researchers at La Jolla Institute for Immunology (LJI) have been named to the 2022 Highly Cited List, released today by Clarivate.
15-Nov-2022 01:05:40 PM EST

Your body remembers common cold coronaviruses from childhood. How can you get the same immunity to COVID-19?

For a glimpse into the future of SARS-CoV-2 immunity, scientists at La Jolla Institute for Immunology (LJI) are investigating how the immune system builds its defenses against common cold coronaviruses (CCCs).
21-Jul-2022 05:25:30 PM EDT

LJI scientists publish first head-to-head comparison of four COVID-19 vaccines

"Just understanding the immune responses to these vaccines will help us integrate what is successful into vaccine designs going forward.”
31-May-2022 02:05:58 PM EDT

Scientists uncover new targets for treating Parkinson's disease

Scientists at La Jolla Institute for Immunology (LJI) have found that people with Parkinson's disease have a clear "genetic signature" of the disease in their memory T cells. The scientists hope that targeting these genes may open the door to new Parkinson's treatments and diagnostics.
18-Mar-2022 02:35:30 PM EDT

Current vaccines teach T cells to fight Omicron

Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2. These T cells can recognize SARS-CoV-2 Variants of Concern, including Delta and Omicron.
24-Jan-2022 11:55:14 AM EST

"New infectious agents originate all the time dating back to the plague in the siege of Athens in the 7th century to the endemic flu in 1918 that killed 20 million people. For medical science, it’s a perennial race between new infectious diseases coming up and society reacting to them, understanding them and ultimately defeating them."

“This study is important because it lets us answer how different vaccine platforms perform in terms of inducing immune responses,” says LJI Professor Alessandro Sette, Dr. Biol. Sci..

- LJI scientists publish first head-to-head comparison of four COVID-19 vaccines

“This work is also exciting because it suggests this is a viable strategy to induce other families of viruses of concern in light of potential future pandemics, such as for example the family of viruses causing influenza, or the ones causing hemorrhagic fevers, or the family of viruses which includes dengue and Zika virus,” says Sette.

- Family resemblance: How T cells could fight many coronaviruses at once

"It is important to learn how people who are HIV-positive respond to infection and vaccination compared to HIV-negative individuals. The present study enables future study to establish this key point”"

- LJI scientists publish first head-to-head comparison of four COVID-19 vaccines

Available for logged-in users onlyLogin HereorRegister

No Video

close
0.08831